Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade
Journal of Clinical Investigation · 16.09.2025 · 135 (18)
DOI: 10.1172/jci185220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 10.07.2025. Verfasst von Imran Khan und 19 weiteren Autor:innen. Beteiligte Einrichtung: California Pacific Medical Center (CPMC) Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Few effective therapeutic options exist after progression on immune checkpoint blockade (ICB) for melanoma. Here, we utilized a platform incorporating transcriptomic profiling, high-throughput drug screening, and murine models to demonstrate the preclinical efficacy of several combinatorial regimens against ICB-resistant melanoma. Transcriptomic analysis of ICB-resistant melanomas demonstrated activation of several targetable pathways. High-throughput drug screening targeting these pathways identified several effective combinations in ICB-resistant patient-derived xenograft models. The combination of cobimetinib and regorafenib (termed Cobi+Reg) emerged as a particularly promising regimen, with efficacy against distinct molecular melanoma subtypes and after progression on ICB in immunocompetent models. Transcriptomic and spatial analysis of Cobi+Reg–treated tumors demonstrated upregulation of antigen presentation machinery, with concomitantly increased activated T cell infiltration. Combining Cobi+Reg with ICB was superior to either modality in vivo. This analytical platform exploits the biology of ICB-resistant melanoma to identify therapeutic vulnerabilities, resulting in the identification of drug combinations that form the basis for rational clinical trial design in the setting of advanced melanoma resistant to ICB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- California Pacific Medical Center (CPMC) Research Institute, San Francisco, California, USA.
- Center for Melanoma Research and Treatment, CPMC, San Francisco, California, USA.
- Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Dermatology, University of California San Francisco, San Francisco, California, USA.
- Melanoma Program, Division of Medical Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Dermatology, Yale University, New Haven, Connecticut, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Khan, I., Rodriguez-Brotons, A., Bhattacharjee, A., Bezrookove, V., Dar, A., De Semir, D., Nosrati, M., Ice, R., Soroceanu, L., Leong, S. P., Kim, K. B., Shi, Y., Cleaver, J. E., Miller, J. R., Desprez, P. Y., Kirkwood, J. M., Bosenberg, M., Salomonis, N., McAllister, S., & Kashani-Sabet, M. (2025). Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. Journal of Clinical Investigation, 135(18). https://doi.org/10.1172/jci185220
Vancouver
Khan I, Rodriguez-Brotons A, Bhattacharjee A, Bezrookove V, Dar A, De Semir D, et al. Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. Journal of Clinical Investigation. 2025;135(18). doi:10.1172/jci185220
BibTeX
@article{Khan2025,
author = {Khan, Imran and Rodriguez-Brotons, Aida and Bhattacharjee, Anukana and Bezrookove, Vladimir and Dar, Altaf and De Semir, David and Nosrati, Mehdi and Ice, Ryan and Soroceanu, Liliana and Leong, Stanley P and Kim, Kevin B and Shi, Yihui and Cleaver, James E and Miller, James R and Desprez, Pierre-Yves and Kirkwood, John M and Bosenberg, Marcus and Salomonis, Nathan and McAllister, Sean and Kashani-Sabet, Mohammed},
title = {Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {18},
doi = {10.1172/jci185220}
}
EUVIMED